The Effect Of Statin On Clinical Progression Of Benign Prostatic Hyperplasia In Patiens With Metabolic Syndrome And Benign Prostatic Hyperplasia

Objectives:This study was to evaluate the effect of simvastatin and atorvastatin on clinical progression of benign prostatic hyperplasia(BPH) in patients with metabolic syndrome(MS) and BPH, compared the different of this effect on those with different level of metabolic factors, and found the new treatment of BPH.Methods:This is a randomized controlled trial. A total of135patients with BPH and MS aged60years or older were enrolled. The patients were divided into a control group received no statins, a group taking simvastatin40mg one day and a group taking atorvastatin20mg one day for one year. The data were collected at the beginning and the end points, including body mass index(BMI), waist, blood pressure(BP), free blood glucose(FBS), triglyceride(TC), total Cholesterol(TC), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), hypersensitive C-reactive protein(hs-CRP), interleukin-6(IL-6), testosterone(T), estradiol(E2), serum prostate specific antigen(PSA), international prostatic symptom score(IPSS) and prostate volume.Results:The level of serum TC, TG, LDL-C, hs-CRP, IL-6, IPSS decreased, the level of serum HDL-C increased, and prostate volume reduced, in patients received simvastatin or atorvastatin for one year. The prostate volume in patients received simvastatin was reduced more than in those received atorvastatin. In the patients with statin, the reduction of prostate volume in obese men was significantly different from that in normal weight men (14.70±5.31ml vs8.16±4.56ml, P<0.05). There was difference of the reduction of prostate volume in men with dyslipidemia and men with normal lipid(13.48±5.78ml vs7.55±2.06ml, P<0.05). The reduction of prostate volume was positively related to the decrease of level of TC and IL-6, and the increase of the level of HDL-C.Conclusions:Simvastatin and atorvastatin have the effect on reducing prostate volume and improving lower urinary tract symptoms, and slowing the clinical progression of BPH. The effect of simvastatin on reducing prostate volume is stronger than that of atorvastatin. Statins can decrease the prostate volume more in obese patients and dyslipidemia patients. The reduction of prostate volume is correlated with the decrease of TC levels, IL-6level and increase of HDL-C levels. Statin possibly through lowering cholesterol and anti-inflammatory improve the clinical progression of benign prostatic hyperplasia.